Pediatric Nephrology

, Volume 1, Issue 2, pp 145–149 | Cite as

Long-term suppression of hyperparathyroidism by phosphate binders in uremic children

  • Koichiro Tamanaha
  • Robert H. K. Mak
  • Susan P. A. Rigden
  • Charles Turner
  • Kathryn M. Start
  • George B. Haycock
  • Cyril Chantler
Original Article


Forty-five children with stable chronic renal failure, not on dialysis, were treated conservatively with a regimen of mild dietary phosphate restriction and high-dose phosphate binders for up to 5 years. Both aluminum hydroxide and calcium carbonate were used initially, but almost all patients were taking calcium carbonate towards the end of the period. Serum immunoreactive parathyroid hormone concentrations were significantly decreased and were within the normal range after 1 year and remained normal during treatment. There was no significant change in renal function over the same treatment period. We conclude that calcium carbonate should be used as the phosphate binder of choice in the long-term suppression of hyperphosphatemia and hyperparathyroidism in uremic children.

Key words

Chronic renal failure Hyperparathyroidism Phosphate binder Aluminum hydroxide Calcium carbonate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Slatopolsky E, Rutherford WE, Hruska K, Martin K, Klahr S (1978) How important is phosphate in the pathogenesis of renal osteodystrophy? Arch Intern Med 138: 848–852PubMedGoogle Scholar
  2. 2.
    Slatopolsky E, Caglar S, Penell JP, Taggart DD, Canterbury JM, Reiss E, Bricker NS (1971) On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 50: 492–499PubMedGoogle Scholar
  3. 3.
    Slatopolsky E, Caglar S, Gradowska J, Canterbury JM, Reiss E, Bricker NS (1972) On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using proportional reduction of dietary phosphorus intake. Kidney Int 2: 147–152PubMedGoogle Scholar
  4. 4.
    Kaplan MA, Canterbury JM, Bourgoignie JJ, Veliz G, Gavellas G, Reiss E, Bricker NS (1979) Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dog. Kidney Int 15: 43–48PubMedGoogle Scholar
  5. 5.
    Andreoli SP, Bergstein JM, Sherrand DJ (1984) Aluminum intoxication from aluminum containing phosphate binders in children with azotemia not undergoing hemodialysis. N Engl J Med 310: 1079–1084PubMedGoogle Scholar
  6. 6.
    Sedman AB, Miller NL, Warady BA, Lunn GM, Alfrey AC (1984) Aluminum loading in children with chronic renal failure. Kidney Int 26: 201–204Google Scholar
  7. 7.
    Clarkson EM, McDonald SJ, De Wardener HJ (1966) The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci 30: 425–438PubMedGoogle Scholar
  8. 8.
    Moriniere PH, Roussel A, Tahiri Y, de Fremont JF, Mautel G, Jandon MC, Gueris J, Fournier A (1982) Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19: 784–787Google Scholar
  9. 9.
    Mak RHK, Turner C, Thompson T, Powell H, Haycock GB, Chantler C (1985) Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminum hydroxide. Br Med J 291: 623–627Google Scholar
  10. 10.
    Woo J, Singer FR (1974) Radioimmunoassay for human parathyroid hormone. Clin Chim Acta 54: 161–168PubMedGoogle Scholar
  11. 11.
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259–263PubMedGoogle Scholar
  12. 12.
    Llach F, Massry S (1985) On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601–606PubMedGoogle Scholar
  13. 13.
    Portale AA, Booth BE, Halloran BP, Curtis Morris R Jr (1984) Effect of dietary phosphorus on circulating concentrations of 1,25 dihydroxy vitamin D and immuno reactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73: 1580–1589PubMedGoogle Scholar
  14. 14.
    Llach F, Massry SG, Koffler A, Malluche HH, Singer FR, Brickman AS, Kurokawa K (1977) Secondary hyperparathyroidism in early renal failure: role of phosphate retention (abstract). Clin Res 25: 507AGoogle Scholar
  15. 15.
    Biswas CK, Arze RS, Ramos JM, Ward MK, Dewar JH, Kerr DN, Kenward DH (1982) Effect of aluminum hydroxide on serum ionised calcium, immunoreactive parathyroid hormone and aluminum in chronic renal failure. Br Med J 284: 776–778Google Scholar
  16. 16.
    Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick S (1982) Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 84: 172–179Google Scholar
  17. 17.
    Alfrey AC, Legendre GR, Kaehny WD (1976) The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294: 184–188PubMedGoogle Scholar
  18. 18.
    Ward MK, Ellis HA, Feest TG, Parkinson IS, Kerr DN (1978) Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminum. Lancet I: 841–845Google Scholar
  19. 19.
    Short AK, Winney RJ, Robson JS (1980) Reversible microcytic hypochromic anaemia in dialysis patients due to aluminum intoxication. Proc Eur Dial Transplant Assoc 17: 226–233PubMedGoogle Scholar
  20. 20.
    Chan JCM, Kodroff MB, Lanwehr DM (1981) Effects of 1,25 dihyroxy vitamin D3 on renal function, mineral status and growth of children with severe chronic renal failure. Pediatrics 68: 559–566PubMedGoogle Scholar
  21. 21.
    Tougaard LE, Sorenson E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AWS (1976) Controlled trial of 1-alpha-hydroxycholecalciferol in chronic renal failure. Lancet I: 1044–1048Google Scholar
  22. 22.
    Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I (1978) Deterioration of renal function during treatment of chronic renal failure with 1,25 dihydroxycholecalciferol. Lancet II: 700–703Google Scholar

Copyright information

© IPNA 1987

Authors and Affiliations

  • Koichiro Tamanaha
    • 1
  • Robert H. K. Mak
    • 1
  • Susan P. A. Rigden
    • 1
  • Charles Turner
    • 1
  • Kathryn M. Start
    • 1
  • George B. Haycock
    • 1
  • Cyril Chantler
    • 1
  1. 1.Evelina Children's Hospital, United Medical Schools of Guy's and St. Thomas HospitalsGuy's HospitalLondonUK

Personalised recommendations